Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FOMX
- CUSIP: N/A
- Web: www.foamix.co.il
- Market Cap: $205.84 million
- Outstanding Shares: 37,426,000
- 50 Day Moving Avg: $4.90
- 200 Day Moving Avg: $5.28
- 52 Week Range: $4.03 - $11.27
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.73
- P/E Growth: 0.00
- Annual Revenue: $5.76 million
- Price / Sales: 35.74
- Book Value: $2.70 per share
- Price / Book: 2.04
- EBIDTA: ($47,960,000.00)
- Net Margins: -823.74%
- Return on Equity: -39.20%
- Return on Assets: -36.76%
- Current Ratio: 9.04%
- Quick Ratio: 9.04%
- Average Volume: 113,850 shs.
- Beta: 1.66
- Short Ratio: 11.78
Frequently Asked Questions for Foamix Pharmaceuticals (NASDAQ:FOMX)
What is Foamix Pharmaceuticals' stock symbol?
Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."
How were Foamix Pharmaceuticals' earnings last quarter?
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) posted its earnings results on Tuesday, August, 8th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.05. The company had revenue of $0.80 million for the quarter, compared to analysts' expectations of $1.50 million. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The firm's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) EPS. View Foamix Pharmaceuticals' Earnings History.
When will Foamix Pharmaceuticals make its next earnings announcement?
Where is Foamix Pharmaceuticals' stock going? Where will Foamix Pharmaceuticals' stock price be in 2017?
2 brokerages have issued 1-year price targets for Foamix Pharmaceuticals' shares. Their predictions range from $9.00 to $12.00. On average, they expect Foamix Pharmaceuticals' share price to reach $10.50 in the next twelve months. View Analyst Ratings for Foamix Pharmaceuticals.
Who are some of Foamix Pharmaceuticals' key competitors?
Some companies that are related to Foamix Pharmaceuticals include Mersana Therapeutics (MRSN), Bellicum Pharmaceuticals (BLCM), Urogen Pharma (URGN), Geron Corporation (GERN), CymaBay Therapeutics (CBAY), BioSpecifics Technologies Corp (BSTC), Corbus Pharmaceuticals Holdings (CRBP), Merus N.V. (MRUS), Ra Pharmctl (RARX), BioTime (BTX), Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Minerva Neurosciences (NERV), Madrigal Pharmaceuticals (MDGL), Oxford BioMedica plc (OXB), Athersys (ATHX), Stemline Therapeutics (STML) and Immune Design Corp. (IMDZ).
Who owns Foamix Pharmaceuticals stock?
Foamix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.03%), AXA (2.53%), Tekla Capital Management LLC (2.50%), Vivo Capital LLC (2.30%), Marshall Wace North America L.P. (1.70%) and Senzar Asset Management LLC (1.53%). View Institutional Ownership Trends for Foamix Pharmaceuticals.
Who sold Foamix Pharmaceuticals stock? Who is selling Foamix Pharmaceuticals stock?
Who bought Foamix Pharmaceuticals stock? Who is buying Foamix Pharmaceuticals stock?
Foamix Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Bank of New York Mellon Corp, AXA, PDT Partners LLC, DAFNA Capital Management LLC, UBS Asset Management Americas Inc. and Franklin Resources Inc.. View Insider Buying and Selling for Foamix Pharmaceuticals.
How do I buy Foamix Pharmaceuticals stock?
Shares of Foamix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Foamix Pharmaceuticals' stock price today?
MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Foamix Pharmaceuticals stock can currently be purchased for approximately $5.50.
Consensus Ratings for Foamix Pharmaceuticals (NASDAQ:FOMX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.50 (90.91% upside)|
Analysts' Ratings History for Foamix Pharmaceuticals (NASDAQ:FOMX)
(Data available from 9/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/24/2017||HC Wainwright||Initiated Coverage||Buy -> Buy||$12.00||High|
|7/19/2017||Credit Suisse Group||Reiterated Rating||Buy||$9.00||Low|
|8/13/2016||Guggenheim||Reiterated Rating||Buy||$10.00 -> $20.00||N/A|
Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)Earnings History by Quarter for Foamix Pharmaceuticals (NASDAQ FOMX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2||($0.39)||($0.44)||$1.50 million||$0.80 million||View||Listen|
|8/10/2016||Q216||($0.25)||($0.27)||$1.10 million||$1.50 million||View||Listen|
|5/10/2016||Q1||($0.23)||($0.15)||$0.53 million||$0.75 million||View||Listen|
|11/11/2015||Q315||($0.20)||($0.11)||$1.50 million||$0.02 million||View||Listen|
|8/19/2015||Q215||($0.14)||($0.18)||$1.00 million||$0.11 million||View||Listen|
|5/12/2015||Q1||($0.12)||($0.14)||$1.00 million||$0.45 million||View||N/A|
|11/14/2014||Q314||($0.07)||($0.12)||$1.00 million||$0.42 million||View||N/A|
Earnings Estimates for Foamix Pharmaceuticals (NASDAQ:FOMX)
Current Year EPS Consensus Estimate: $-1.53 EPS
Next Year EPS Consensus Estimate: $-0.96 EPS
Dividend History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Foamix Pharmaceuticals (NASDAQ:FOMX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Foamix Pharmaceuticals (NASDAQ:FOMX)
Latest Headlines for Foamix Pharmaceuticals (NASDAQ:FOMX)
Foamix Pharmaceuticals (FOMX) Chart for Friday, September, 22, 2017